Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.


Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
10 2019
Historique:
received: 14 01 2019
revised: 28 06 2019
accepted: 01 08 2019
pubmed: 14 8 2019
medline: 21 10 2020
entrez: 13 8 2019
Statut: ppublish

Résumé

Two new series of compounds were designed and synthesized as potent PARP-1 inhibitors. These compounds were evaluated for PARP-1 enzyme and cellular inhibitory activities. All efforts lead to the identification of 9k (named as LG-12) with efficient potency both for PARP-1 and BRCA1 deficient MDA-MB-436 cells. Additionally, the novel PARP-1 inhibitor LG-12 is an efficient chemosensitizer, which could potentiate the anti-cancer effect of TMZ. Our data presented herein provide a comprehensive preclinical in vitro evaluation of the potential therapeutic efficacy and potency of chemotherapeutic agent-PARP-1 inhibitor combinations for LG-12. The combined results indicated that LG-12 could be a promising candidate for further study.

Identifiants

pubmed: 31404795
pii: S0045-2068(19)30065-3
doi: 10.1016/j.bioorg.2019.103181
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Imidazoles 0
Phthalazines 0
Poly(ADP-ribose) Polymerase Inhibitors 0
Thiohydantoins 0
PARP1 protein, human EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103181

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Yi Zhong (Y)

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.

Ying Meng (Y)

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.

Xi Xu (X)

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.

Lulu Zhao (L)

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.

Zhiyu Li (Z)

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.

Qidong You (Q)

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China. Electronic address: youqd@163.com.

Jinlei Bian (J)

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China. Electronic address: bianjl@cpu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH